# Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

> **NCT02426086** · PHASE2 · COMPLETED · sponsor: **Geron Corporation** · enrollment: 107 (actual)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Imetelstat 4.7 mg/kg
- **DRUG:** Imetelstat 9.4 mg/kg

## Key facts

- **NCT ID:** NCT02426086
- **Lead sponsor:** Geron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-28
- **Primary completion:** 2018-04-26
- **Final completion:** 2020-02-07
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2021-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02426086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02426086, "Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02426086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*